PIQRAY alpelisib 250 mg daily dose blister (200+50 mg tablet) composite pack Australia - English - Department of Health (Therapeutic Goods Administration)

piqray alpelisib 250 mg daily dose blister (200+50 mg tablet) composite pack

novartis pharmaceuticals australia pty ltd - alpelisib, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; sodium starch glycollate; hypromellose; magnesium stearate; purified talc; macrogol 4000; iron oxide black; iron oxide red; titanium dioxide - piqray in combination with fulvestrant, is indicated for the treatment of postmenopausal women, and men, with hormone receptor positive, her2-negative, advanced or metastatic breast cancer with a pik3ca mutation as detected by a validated test following progression on or after an endocrine-based regimen

PIQRAY alpelisib 200 mg daily dose blister (200 mg tablet) Australia - English - Department of Health (Therapeutic Goods Administration)

piqray alpelisib 200 mg daily dose blister (200 mg tablet)

novartis pharmaceuticals australia pty ltd - alpelisib, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; sodium starch glycollate; hypromellose; magnesium stearate; purified talc; macrogol 4000; iron oxide black; iron oxide red; titanium dioxide - piqray in combination with fulvestrant, is indicated for the treatment of postmenopausal women, and men, with hormone receptor positive, her2-negative, advanced or metastatic breast cancer with a pik3ca mutation as detected by a validated test following progression on or after an endocrine-based regimen

PIQRAY alpelisib 300 mg daily dose blister (150 mg tablet) Australia - English - Department of Health (Therapeutic Goods Administration)

piqray alpelisib 300 mg daily dose blister (150 mg tablet)

novartis pharmaceuticals australia pty ltd - alpelisib, quantity: 150 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; sodium starch glycollate; hypromellose; magnesium stearate; purified talc; macrogol 4000; iron oxide black; iron oxide red; titanium dioxide - piqray in combination with fulvestrant, is indicated for the treatment of postmenopausal women, and men, with hormone receptor positive, her2-negative, advanced or metastatic breast cancer with a pik3ca mutation as detected by a validated test following progression on or after an endocrine-based regimen

Mask, surgical, single use Australia - English - Department of Health (Therapeutic Goods Administration)

mask, surgical, single use

iqr group pty ltd -

PIQRAY 150 MG Israel - English - Ministry of Health

piqray 150 mg

novartis israel ltd - alpelisib - film coated tablets - alpelisib 150 mg - alpelisib - piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, pik3camutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen

PIQRAY 200 MG Israel - English - Ministry of Health

piqray 200 mg

novartis israel ltd - alpelisib - film coated tablets - alpelisib 200 mg - alpelisib - piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, pik3camutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen

PIQRAY 50 MG Israel - English - Ministry of Health

piqray 50 mg

novartis israel ltd - alpelisib - film coated tablets - alpelisib 50 mg - alpelisib - piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, pik3camutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen

VasoKINOX nitric oxide 450 ppm mol/mol medicinal gas compressed gas cylinder Australia - English - Department of Health (Therapeutic Goods Administration)

vasokinox nitric oxide 450 ppm mol/mol medicinal gas compressed gas cylinder

air liquide healthcare pty ltd - nitric oxide, quantity: 0.0004 mol - gas, medicinal - excipient ingredients: nitrogen - vasokinox is indicated in conjunction with ventilator support and other appropriate active substances to selectively decrease pulmonary arterial pressure in patients with perioperative pulmonary hypertension in conjunction with heart surgery

DESVENLAFAXINE SANDOZ desvenlafaxine 50mg modified release tablets blister Australia - English - Department of Health (Therapeutic Goods Administration)

desvenlafaxine sandoz desvenlafaxine 50mg modified release tablets blister

medis pharma pty ltd - desvenlafaxine, quantity: 50 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; hypromellose; citric acid monohydrate; magnesium stearate; povidone; purified talc; alginic acid; titanium dioxide; macrogol 6000; iron oxide red - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.

DESVENLAFAXINE SANDOZ desvenlafaxine 100mg modified release tablets blister Australia - English - Department of Health (Therapeutic Goods Administration)

desvenlafaxine sandoz desvenlafaxine 100mg modified release tablets blister

medis pharma pty ltd - desvenlafaxine, quantity: 100 mg - tablet, modified release - excipient ingredients: alginic acid; magnesium stearate; povidone; purified talc; hypromellose; citric acid monohydrate; microcrystalline cellulose; titanium dioxide; macrogol 8000; iron oxide red; iron oxide black - for the treatment of major depressive disorder, including the preventiton of relapse. not indicated for paediatric use.